drugset / Trial / NCT06656598
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Timeline
- Start
- 2025-11-07
- Primary completion
- 2028-09
- Completion
- 2032-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |